Dark urine on waking shows up in about 60 to 70 percent of people with classical PNH, yet fatigue affects 80 to 90 percent, making symptoms look more like a daily weight than a rare hemolysis event. Behind that gap are measurable markers and modern management numbers, from LDH above 3 times the upper limit in 95 percent to thrombosis risk dropping 87 percent with eculizumab. With prevalence around 1 to 2 cases per million worldwide and a median diagnosis age of 32, these statistics help explain why PNH can feel inconsistent until you map the full dataset.
Key Takeaways
- Dark urine upon waking reported in 60-70% of classical PNH patients.
- Fatigue is the most common symptom, affecting 80-90% of PNH patients.
- Abdominal pain occurs in 50-60% due to smooth muscle spasm from NO depletion.
- Flow cytometry shows PNH RBCs <1% sensitive for diagnosis.
- FLAER assay detects GPI deficiency on granulocytes with 99% sensitivity.
- LDH >3x ULN present in 95% of classical PNH.
- Paroxysmal nocturnal hemoglobinuria (PNH) has a prevalence of approximately 1-2 cases per million population worldwide.
- In the United States, the annual incidence of PNH is estimated at 0.13 per million individuals.
- PNH affects approximately 5-10 people per million in Europe according to population-based studies.
- PNH arises from somatic mutation in PIGA gene on X chromosome in hematopoietic stem cells.
- Deficiency of GPI-anchored proteins like CD55 and CD59 leads to complement-mediated lysis.
- Intravascular hemolysis in PNH is driven by C3 convertase stabilization due to CD55 loss.
- 5-year survival >95% with C5 inhibitors vs 65% untreated.
- Thrombosis risk reduced 87% with eculizumab (0.62 vs 7.43 events/100 pt-yrs).
- Renal failure progression halted in 70% on terminal complement inhibitors.
PNH is rare and often presents with fatigue and dark urine, and modern complement therapies dramatically improve survival.
Related reading
01 · Category
Clinical Presentation25 stats
01
Dark urine upon waking reported in 60-70% of classical PNH patients.
02
Fatigue is the most common symptom, affecting 80-90% of PNH patients.
03
Abdominal pain occurs in 50-60% due to smooth muscle spasm from NO depletion.
04
Dysphagia and esophageal spasm reported in 25-35% of hemolytic patients.
05
Thrombosis in unusual sites (hepatic vein, dermal) in 15-20% of cases.
06
Anemia (Hb <10 g/dL) present in 70% at diagnosis.
07
Headache occurs in 40% linked to pulmonary hypertension and NO scavenging.
08
Bone marrow failure symptoms (pancytopenia) in 30-40% of patients.
09
Renal impairment (GFR <60 mL/min) develops in 30-65% over time.
10
Smooth muscle dystonias (erectile dysfunction in males 50%).
11
Pulmonary hypertension detected in 35% by echocardiography.
12
Jaundice intermittent in 20-30% during hemolytic crises.
13
Back pain from renal hemosiderosis in 15-25% chronic cases.
14
Infections secondary to neutropenia in 20% with BMF association.
15
Leg ulcers rare but occur in 5-10% severe hemolytic patients.
16
Impotence in 40-50% of male patients due to vasculopathy.
17
Shortness of breath on exertion in 60% from anemia/PHTN.
18
Budd-Chiari syndrome in 10-15% as presenting thrombosis.
19
Pruritus after hemoglobinuria in 30% of episodes.
20
Cognitive symptoms (confusion) from anemia in 10-15% severe cases.
21
Pregnancy complications (fetal loss 20-30%) in PNH mothers.
22
Splenomegaly absent in pure hemolytic PNH but present in 20% BMF.
23
Chest pain from esophageal spasm in 20%.
24
Chronic kidney disease stage 3+ in 50% untreated >10 years.
25
Hemolytic crises triggered by infections in 40% of patients.
Interpretation
Clinical Presentation Interpretation
Clinically, PNH is most often marked by fatigue in 80 to 90% of patients and anemia with Hb under 10 g/dL in 70% at diagnosis, with classic dark urine on waking in 60 to 70% further reinforcing the strong overall symptom pattern.
02 · Category
Diagnosis23 stats
01
Flow cytometry shows PNH RBCs <1% sensitive for diagnosis.
02
FLAER assay detects GPI deficiency on granulocytes with 99% sensitivity.
03
LDH >3x ULN present in 95% of classical PNH.
04
Sucrose lysis test positive in 70-80% but nonspecific.
05
Ham's acidified serum test specificity 95% but low sensitivity.
06
Clone size measured by WBC GPI-AP loss >10% diagnostic.
07
Reticulocyte count >3% and absolute reticulocyte count >100 x10^9/L.
08
Haptoglobin undetectable in 90% during active hemolysis.
09
Urinary iron loss 10-30 mg/day in hemolytic PNH.
10
MRI detects renal cortical hemosiderosis in 65% chronic patients.
11
Bone marrow biopsy shows erythroid hyperplasia in 80% hemolytic type.
12
CD55/CD59 dual stain by flow cytometry gold standard (sensitivity 97%).
13
PNH clone on monocytes >20% high risk for thrombosis.
14
Bilirubin (unconj) 2-5x ULN in 85% classical cases.
15
High-sensitivity FLAER detects clones as small as 0.01%.
16
DAT negative in intravascular hemolysis distinguishing from AIHA.
17
Serum EPO low despite anemia in 40% due to inappropriate response.
18
Thrombocytopenia <100 x10^9/L in 30% at presentation.
19
MRI T2* gradient echo for renal iron quantification.
20
Leukocyte telomere length shortened in PNH with AA.
21
Next-gen sequencing confirms PIGA mutations in 95% of clones.
22
Absolute reticulocyte count >150 x10^9/L supports hemolytic PNH.
23
Granulocyte clone size >50% predicts LDH >10x ULN.
Interpretation
Diagnosis Interpretation
For diagnosis, the most reliable signal is a FLAER assay detecting GPI deficiency on granulocytes with 99% sensitivity, while other common tests vary widely in sensitivity and specificity such as Ham’s acidified serum specificity at 95% but low sensitivity and LDH elevation above 3 times the ULN occurring in 95% of classical PNH.
03 · Category
Epidemiology30 stats
01
Paroxysmal nocturnal hemoglobinuria (PNH) has a prevalence of approximately 1-2 cases per million population worldwide.
02
In the United States, the annual incidence of PNH is estimated at 0.13 per million individuals.
03
PNH affects approximately 5-10 people per million in Europe according to population-based studies.
04
The median age at diagnosis of PNH is 32 years, with a range from 15 to 75 years.
05
PNH shows no significant gender predilection, with a male-to-female ratio of approximately 1:1.
06
In Japan, PNH incidence is reported as 0.075 per million per year based on national registries.
07
Approximately 15-20% of PNH patients are diagnosed before the age of 20.
08
PNH is more commonly associated with bone marrow failure syndromes in 40-50% of cases.
09
Global prevalence estimates suggest around 8,000-10,000 patients worldwide.
10
In a French cohort, PNH prevalence was 1.3 per million.
11
PNH clonal size >50% GPI-deficient granulocytes correlates with hemolytic phenotype in 70% of cases.
12
Median survival for classical PNH is 10-15 years from diagnosis without treatment.
13
Thrombotic events occur in 30-40% of untreated PNH patients.
14
Bone marrow failure precedes PNH diagnosis in about 25% of patients.
15
PNH type III cells (complete GPI deficiency) are found in 90% of hemolytic cases.
16
Annual incidence in children under 18 is less than 0.05 per million.
17
In AA Asia, PNH is underdiagnosed with prevalence <1 per million.
18
50-60% of PNH patients have subclinical disease with small clones.
19
Median time from symptom onset to PNH diagnosis is 1-2 years.
20
PNH is present in 20-30% of patients with aplastic anemia.
21
Prevalence of PNH clones >1% in general population is 0.02%.
22
In a UK registry, 150 new PNH cases were identified over 10 years.
23
Female patients represent 52% of diagnosed PNH cases in US registries.
24
PNH incidence peaks in the 30-40 age group at 0.2 per million.
25
10% of PNH patients develop myelodysplastic syndrome over 10 years.
26
Historical data shows 25% mortality within 5 years pre-eculizumab.
27
PNH in pregnant women occurs in 5-10% of female patients aged 20-40.
28
Sub-Saharan Africa reports higher PNH rates linked to infections at 2 per million.
29
35% of PNH patients have coexisting autoimmune disorders.
30
Median diagnostic delay in resource-poor settings is 3-5 years.
Interpretation
Epidemiology Interpretation
Across epidemiology reports worldwide, PNH remains a rare disease with prevalence around 1 to 2 cases per million and incidence roughly 0.13 per million per year in the United States, peaking in diagnostic detection at a median age of 32 years.
More related reading
04 · Category
Pathophysiology24 stats
01
PNH arises from somatic mutation in PIGA gene on X chromosome in hematopoietic stem cells.
02
Deficiency of GPI-anchored proteins like CD55 and CD59 leads to complement-mediated lysis.
03
Intravascular hemolysis in PNH is driven by C3 convertase stabilization due to CD55 loss.
04
Thrombophilia in PNH results from platelet activation and free hemoglobin scavenging NO.
05
PIGA mutation rate is estimated at 10^-6 per hematopoietic stem cell division.
06
Type I PNH cells have partial GPI deficiency (10-20% normal levels).
07
CD59 loss increases MAC formation by 50-100 fold in PNH erythrocytes.
08
Nocturnal exacerbation linked to mild respiratory acidosis increasing C3 saturation.
09
Bone marrow failure in PNH associated with immune attack on GPI-deficient clones.
10
Free hemoglobin induces hypertension via NO depletion in 60% of hemolytic patients.
11
Lactate dehydrogenase (LDH) elevation >10x ULN in 80% classical PNH.
12
Complement activation generates anaphylatoxins C3a/C5a promoting inflammation.
13
PNH clones expand due to type I interferon hypersensitivity of mutant HSCs.
14
Urinary haemosiderin present in 90% of patients with ongoing hemolysis.
15
Reduced CD55/CD59 on granulocytes predicts thrombosis risk (clone size >60%).
16
Erythrocyte membrane stress from complement leads to 1-2% daily RBC destruction.
17
PIGA mutations are hypomorphic, allowing clonal dominance without apoptosis.
18
Macrophage activation by hemolysis contributes to bone marrow fibrosis in 20%.
19
C5 inhibition reduces hemolysis by 90% but residual extravascular hemolysis occurs.
20
GPI-AP loss affects 20+ proteins including urokinase receptor linked to thrombosis.
21
Hemoglobinuria episodes average 3-5 per week in untreated classical PNH.
22
Nitric oxide scavenging by Hb causes smooth muscle dystonia and dysphagia.
23
PNH HSCs evade immune surveillance via reduced CD55/CD59 signaling.
24
Reticulocyte count elevated >10% in 70% due to compensatory erythropoiesis.
Interpretation
Pathophysiology Interpretation
Pathophysiology in PNH stems from a PIGA somatic mutation occurring at about 10^-6 per hematopoietic stem cell division, producing partial GPI-anchored protein loss such as CD55 and CD59 in which even Type I cells with only 10 to 20% of normal levels can drive complement mediated hemolysis and thrombophilia through C3 convertase stabilization.
05 · Category
Prognosis18 stats
01
5-year survival >95% with C5 inhibitors vs 65% untreated.
02
Thrombosis risk reduced 87% with eculizumab (0.62 vs 7.43 events/100 pt-yrs).
03
Renal failure progression halted in 70% on terminal complement inhibitors.
04
Median survival >25 years with modern anti-C5 therapy.
05
Cumulative thrombosis incidence 40% at 10 years untreated.
06
Post-BMT relapse of PNH clone <5% with myeloablative conditioning.
07
LDH control >90% correlates with 80% transfusion independence.
08
10-year OS 97% in ravulizumab switchers from eculizumab.
09
Aplastic anemia evolution in subclinical PNH 15-20% over 5 years.
10
Pregnancy success rate 67% with complement inhibition.
11
Pulmonary HTN regresses in 50% after sustained LDH control.
12
AML transformation risk 2-5% lifetime in classical PNH.
13
Fatigue resolution in 75% achieving Hb >10 g/dL.
14
ESRD incidence <5% with early complement blockade.
15
Clone size stability in 60% on long-term C5i without expansion.
16
Survival benefit NNT=3 for eculizumab vs supportive care.
17
Thrombotic mortality reduced from 22% to 1% post-eculizumab.
18
Renal recovery (eGFR improvement) in 33% after 2 years therapy.
Interpretation
Prognosis Interpretation
With prognosis, modern complement inhibition dramatically improves outcomes, boosting 5-year survival to over 95% versus 65% untreated and cutting thrombosis risk by about 87% while also halting renal failure progression in around 70% of patients.
06 · Category
Treatment23 stats
01
Eculizumab reduces LDH by 85-90% within 1 week of initiation.
02
Ravulizumab every 8 weeks maintains LDH control in 96% of patients.
03
Bone marrow transplant cures PNH in 70-80% matched sibling donors.
04
Pegcetacoplan reduces transfusion dependence by 85% in phase 3 trials.
05
Folic acid supplementation recommended at 5 mg daily for all hemolytic patients.
06
Iron chelation with deferasirox for serum ferritin >500 ng/mL.
07
Anticoagulation with warfarin for thrombosis history (target INR 2-3).
08
Iptacopan (C3 inhibitor) normalizes Hb in 80% without transfusions.
09
Immunosuppression with ATG/cyclosporine for PNH with AA in 60% response.
10
Vaccinations (meningococcal, pneumococcal) mandatory pre-C5i >90% compliance.
11
Crovalimab subcutaneous C5i sustains LDH <1.5x ULN in 85%.
12
RBC transfusions average 4-6 units/year pre-treatment reduced to 0.5 post-C5i.
13
Prophylactic anticoagulation in high-risk (clone >50%) reduces events by 80%.
14
Danicopan add-on triples proximal C3 inhibition efficacy.
15
HSCT 5-year survival 80% in pediatric PNH.
16
Eculizumab breakthrough hemolysis in 10% managed with 600mg dose.
17
Renal function stabilizes (eGFR +5 mL/min) after 1 year C5 inhibition.
18
Anti-C5 antibody development <1% with long-term eculizumab.
19
Eltrombopag response in thrombocytopenic PNH 40-50%.
20
Meningococcal prophylaxis with antibiotics lifelong in C5i users.
21
Survival post-BMT 90% if no prior thrombosis.
22
LDH normalization (<1.5x ULN) breakthrough threshold for rescue dosing.
23
Quality of life (FACIT-F) improves by 10 points post-eculizumab.
Interpretation
Treatment Interpretation
In the Treatment category, targeted therapies and supportive care show strong improvements, with eculizumab cutting LDH by 85 to 90% within a week and ravulizumab maintaining LDH control in 96% of patients, while transfusion dependence falls by 85% with pegcetacoplan and transplant cures 70 to 80% of matched sibling cases.
report visual · Breakdown
PNH: How common symptoms and complications are
A large share of PNH patients experience hallmark symptoms (fatigue, dark urine, abdominal pain) alongside clinically important complications such as thrombosis and renal impairment.
70%
Anemia (Hb <10 g/dL) present in 70% at diagnosis.
30%
Pruritus after hemoglobinuria in 30% of episodes.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Pnh Statistics. Gitnux. https://gitnux.org/pnh-statistics
MLA
Henrik Dahl. "Pnh Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pnh-statistics.
Chicago
Henrik Dahl. 2026. "Pnh Statistics." Gitnux. https://gitnux.org/pnh-statistics.
Sources & references
6 datasets cited across this report · attribution is report-level